文献速递关节外科创伤骨科

术后唑吡坦使用对初次全膝关节置换术的影响:基于私人保险数据库的回顾性匹配对照分析

Impact of Postoperative Zolpidem Use on Primary Total Knee Arthroplasty: A Retrospective Matched-Controlled Analysis of a Private Insurance Database.
PubMed 文献 · J Arthroplasty · 2020-11-04

本研究利用私人保险数据库回顾性分析初次全膝关节置换术(TKA)后使用唑吡坦的患者,按1:5匹配 demographics 和合并症后纳入99,178例研究组和495,795例对照。结果显示唑吡坦使用与医疗并发症(OR 1.76)、植入物并发症(OR 1.35)和90天跌倒风险(OR 1.16)升高相关,再入院率无显著差异。

要点

  • TKA术后使用唑吡坦与医疗并发症风险升高相关(OR 1.76, 95%CI 1.71-1.82)。
  • 唑吡坦使用与植入物并发症风险升高相关(OR 1.35, 95%CI 1.23-1.47)。
  • 唑吡坦使用与90天跌倒风险升高相关(OR 1.16, 95%CI 1.11-1.21)。

核心结论

  • 初次TKA后使用唑吡坦与并发症发病率和跌倒风险升高相关。

研究设计与样本

  • 回顾性匹配对照分析,使用私人保险数据库,研究组为术后使用唑吡坦的TKA患者,对照组为无催眠药使用史的初次TKA患者,按人口学和合并症1:5匹配。
  • 研究组99,178例,对照组495,795例,主要终点为90天医疗和植入物并发症、跌倒风险和再入院。

主要发现

  • 研究组医疗并发症 odds 升高(OR: 1.76, 95% CI: 1.71-1.82, P < .0001)。
  • 研究组植入物并发症 odds 升高(OR: 1.35, 95% CI: 1.23-1.47, P < .0001)。
  • 研究组90天跌倒风险升高(OR: 1.16, 95% CI: 1.11-1.21, P < .0001)。
  • 再入院率与对照组相似(5.10% vs 4.84%, P = .12)。

关键数值与推荐

  • 医疗并发症 OR: 1.76, 95% CI: 1.71-1.82, P < .0001。
  • 植入物并发症 OR: 1.35, 95% CI: 1.23-1.47, P < .0001。
  • 90天跌倒 OR: 1.16, 95% CI: 1.11-1.21, P < .0001。
  • 再入院率 5.10% vs 4.84%, P = .12。

临床怎么用

  • 骨科医生与患者在TKA术前决策讨论中可考虑术后唑吡坦使用的相关风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Zolpidem has gained popularity as a pharmaceutical therapy for insomnia, being the most prescribed hypnotic in the United States today. However, it is associated with increased mortality and morbidity. Literature regarding zolpidem use in the total knee arthroplasty (TKA) population is limited. The aim of the study was to analyze postoperative zolpidem use in the TKA population regarding medical and implant complications, falls, and readmission. METHODS: The study group was queried according to zolpidem use. Controls consisted of patients who underwent primary TKA without a history of hypnotic drug use. Study group patients were matched to controls in a 1:5 ratio by demographics and comorbidities. Results yielded 99,178 study participants and 495,795 controls. Primary endpoints included 90-day medical and implant complications, fall risk, and readmission. Chi-squared test was used to compare categorical variables. Multivariate logistic regression was used to calculate odds (OR) for complications, fall risk, and readmission. A P value less than 0.05 was considered statistically significant. RESULTS: Study group patients had increased odds of medical complications (OR: 1.76, 95% CI: 1.71-1.82, P < .0001) and implant complications (OR: 1.35, 95% CI: 1.23-1.47, P < .0001) compared to controls. Furthermore, patients in the study group were found to have an increased risk of 90- day falls (OR: 1.16, 95% CI: 1.11-1.21, P < .0001). Readmission was similar to controls (5.10% vs 4.84%, P = .12). CONCLUSION: Zolpidem use following primary TKA is associated with the risk of morbidity and falls. The findings are consistent with the literature regarding zolpidem. These findings may affect discussion between orthopedic surgeons and patients in the decision-making process prior to undergoing TKA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Ardeljan AD, Polisetty TS, Palmer JR, et al. Impact of Postoperative Zolpidem Use on Primary Total Knee Arthroplasty: A Retrospective Matched-Controlled Analysis of a Private Insurance Database. J Arthroplasty. 2020. PMID: 33250327. doi:10.1016/j.arth.2020.10.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。